Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Filetti

Showing results (41-50 of 81) with videos related to

Pageof 9
Sort By:
The Oncologist|June 26, 2025
The financial toll of cancer: uncovering the links between financial toxicity and symptom burdenMarco Filetti, Pasquale Lombardi, Gabriella Gentile, et al.
Frontiers in Oncology|April 17, 2026
Artificial intelligence in oncology publishing: a systematic review and policy analysis of high-impact journalsRaffaele Giusti, Marco Filetti, Pasquale Lombardi, et al.
Pathologica|October 8, 2024
A preliminary study on the diagnostic performance of the uPath PD-L1 (SP263) artificial intelligence (AI) algorithm in patients with NSCLC treated with PD-1/PD-L1 checkpoint blockadeAlessio Cortellini, Claudia Zampacorta, Michele De Tursi, et al.
Endocrine|February 13, 2020
Exploring the molecular insights of concurrent composite mucoepidermoid carcinoma and papillary thyroid carcinomaRosa Falcone, Marialuisa Sponziello, Raffella Carletti, et al.
Endocrine|March 25, 2020
Correction to: Exploring the molecular insights of concurrent composite mucoepidermoid carcinoma and papillary thyroid carcinomaRosa Falcone, Marialuisa Sponziello, Raffella Carletti, et al.
Cancers|December 17, 2024
Exploring Genomic Biomarkers for Pembrolizumab Response: A Real-World Approach and Patient Similarity Network Analysis Reveal DNA Response and Repair Gene Mutations as a SignatureMarco Filetti, Mario Occhipinti, Alessio Cirillo, et al.
European Journal of Cancer (Oxford, England : 1990)|July 2, 2025
Performance status eligibility requirements and enrollment characteristics in cancer clinical trials leading to US Food and Drug Administration drugs approval (2009-2023)Giovanni Maria Iannantuono, Charalampos S Floudas, Marco Filetti, et al.
Frontiers in Oncology|December 7, 2020
High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone MetastasesMarta Laganà, Cristina Gurizzan, Elisa Roca, et al.
Journal of the National Cancer Institute|March 28, 2026
Temporal Patterns and Factors Associated with Early Termination in Phase 1 Clinical Trials for Solid TumorsGiovanni Maria Iannantuono, Stefano Sganga, Tommaso Giovagnoli, et al.
Cancers|October 28, 2023
Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors: Impact on Efficacy and SurvivalKhalil Choucair, Caroline Nebhan, Alessio Cortellini, et al.
Pageof 9

Showing results (41-50 of 81) with videos related to

Sort By:
Pageof 9
The Oncologist|June 26, 2025
The financial toll of cancer: uncovering the links between financial toxicity and symptom burdenMarco Filetti, Pasquale Lombardi, Gabriella Gentile, et al.
Frontiers in Oncology|April 17, 2026
Artificial intelligence in oncology publishing: a systematic review and policy analysis of high-impact journalsRaffaele Giusti, Marco Filetti, Pasquale Lombardi, et al.
Pathologica|October 8, 2024
A preliminary study on the diagnostic performance of the uPath PD-L1 (SP263) artificial intelligence (AI) algorithm in patients with NSCLC treated with PD-1/PD-L1 checkpoint blockadeAlessio Cortellini, Claudia Zampacorta, Michele De Tursi, et al.
Endocrine|February 13, 2020
Exploring the molecular insights of concurrent composite mucoepidermoid carcinoma and papillary thyroid carcinomaRosa Falcone, Marialuisa Sponziello, Raffella Carletti, et al.
Endocrine|March 25, 2020
Correction to: Exploring the molecular insights of concurrent composite mucoepidermoid carcinoma and papillary thyroid carcinomaRosa Falcone, Marialuisa Sponziello, Raffella Carletti, et al.
Cancers|December 17, 2024
Exploring Genomic Biomarkers for Pembrolizumab Response: A Real-World Approach and Patient Similarity Network Analysis Reveal DNA Response and Repair Gene Mutations as a SignatureMarco Filetti, Mario Occhipinti, Alessio Cirillo, et al.
European Journal of Cancer (Oxford, England : 1990)|July 2, 2025
Performance status eligibility requirements and enrollment characteristics in cancer clinical trials leading to US Food and Drug Administration drugs approval (2009-2023)Giovanni Maria Iannantuono, Charalampos S Floudas, Marco Filetti, et al.
Frontiers in Oncology|December 7, 2020
High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone MetastasesMarta Laganà, Cristina Gurizzan, Elisa Roca, et al.
Journal of the National Cancer Institute|March 28, 2026
Temporal Patterns and Factors Associated with Early Termination in Phase 1 Clinical Trials for Solid TumorsGiovanni Maria Iannantuono, Stefano Sganga, Tommaso Giovagnoli, et al.
Cancers|October 28, 2023
Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors: Impact on Efficacy and SurvivalKhalil Choucair, Caroline Nebhan, Alessio Cortellini, et al.
Pageof 9